RP1-13D10.2 Is a Novel Modulator of Statin-Induced Changes in Cholesterol
Author(s) -
Katrina Mitchel,
Elizabeth Theusch,
Celia Cubitt,
Andrea C. Dosé,
Kristen N. Stevens,
Devesh Naidoo,
Marisa W. Medina
Publication year - 2016
Publication title -
circulation cardiovascular genetics
Language(s) - English
Resource type - Journals
eISSN - 1942-3268
pISSN - 1942-325X
DOI - 10.1161/circgenetics.115.001274
Subject(s) - simvastatin , rosuvastatin , statin , ldl receptor , cholesterol , single nucleotide polymorphism , biology , apolipoprotein b , genetics , chemistry , microbiology and biotechnology , lipoprotein , medicine , endocrinology , pharmacology , gene , biochemistry , genotype
Numerous genetic contributors to cardiovascular disease risk have been identified through genome-wide association studies; however, identifying the molecular mechanism underlying these associations is not straightforward. The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial of rosuvastatin users identified a sub-genome-wide association of rs6924995, a single-nucleotide polymorphism ≈10 kb downstream of myosin regulatory light chain interacting protein (MYLIP, aka IDOL and inducible degrader of low-density lipoprotein receptor [LDLR]), with LDL cholesterol statin response. Interestingly, although this signal was initially attributed to MYLIP, rs6924995 lies within RP1-13D10.2, an uncharacterized long noncoding RNA.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom